Skip to content

Released Nov 1, 2021, after the close

10-Q filed Nov 12, 2021, 43 days after period end · 0000950170-21-004267

Q3 2021 · 10-Q
Revenue—
Net Income-$5.98MN/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$0.10N/M vs Q3 2020N/M vs Q2 2021
Operating Income-$5,854,000N/M
Operating Cash Flowderived-$3,457,000N/M
Free Cash Flowderived-$3,824,000N/M

What the release said

The release

Same quarter

MetricQ3 2021Q3 2020Q3 2019
Net Income-$5.98M-$9.15M-$8.55M
EPS Diluted-$0.10-$0.18-$1.27

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR